Kinase inhibitors and their uses

Details Kinase inhibitors and their uses Kinase inhibitors and their uses

2009-09-01

2011-11-08

Moore, Susanna (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S266400, C514S265100, C544S292000, C544S280000, C544S117000

Reexamination Certificate

active

08053434

ABSTRACT:
The present disclosure provides compounds that inhibit protein kinases, such as JAK, Axl, or Syk kinases, compositions comprising the compounds and methods of using the compounds to inhibit protein kinase and treat and/or prevent diseases associated with inappropriate kinase activity. The compounds of the present invention are according to structural formula (I):or a salt or N-oxide thereof, whereinB is selected from

REFERENCES:
patent: 7041824 (2006-05-01), Bordon-Pallier et al.
patent: 2005/0176707 (2005-08-01), Chen et al.
patent: 2006/0035891 (2006-02-01), Li et al.
patent: WO 97/16452 (1997-05-01), None
patent: WO 00/49018 (2000-08-01), None
patent: WO 2001/009134 (2001-02-01), None
patent: WO 2001/032632 (2001-05-01), None
patent: WO 2004043367 (2002-11-01), None
patent: WO 02/102314 (2002-12-01), None
patent: WO 2004/037823 (2004-05-01), None
patent: WO 2005/016528 (2005-02-01), None
patent: WO 2005/004752 (2005-05-01), None
patent: WO 2005/049616 (2005-06-01), None
patent: WO 2005/097135 (2005-10-01), None
patent: WO 2005/118544 (2005-12-01), None
patent: WO 2006/055528 (2006-05-01), None
patent: WO 2006/055561 (2006-05-01), None
Perreira et al.: “Reversine: and its 2-Substituted Adenine Derivatives as Potent and Selective A3 Adenosine Receptor Antagonists,” J. Med. Chem., 2005, 48 (15), p. 4910-4918.
Goldman et al., N. England J. Med. 344, 14, Apr. 5, 2001.
Ekman et al., Oncogene (2000) 19, 4151-58.
Xu et al., J. Biol. Chem., 273, 50, Dec. 11, 1998. 33230-38.
Zhang et al., J. Biol. Chem., vol. 279, No. 53, Dec. 31, 2004, pp. 55348-55354.
Lopes de Menezes et al., Clin. Cancer Res. 2005:11 (14), Jul. 15, 2005, 5281-91.
Kawahara et al., J. Clin. Onc., 2006 ASCO Annual Meeting Proceedings, Part I, vol. 24, No. 18S, Jun. 20, 2006, 13163.
Yoshida et al., J. Neurochem., 2004, 90, 352-58.
Brandlin et al., J. Biol. Chem., vol. 277, No. 8, 2002, 6490-6496.
Wu et al., Am. J. Pathol., 156, Jun. 6, 2000.
Rane et al., Oncogene (2000) 19, 5662-5679.
Oshiro et al., Clinical Cancer Research, vol. 7, 4262-4271, Dec. 2001.
Nakano et al., FEBS Letters, 387 (1996) 75-77.
Kyttaris et al., Clin. Immunol. Sep. 2007, 124(3): 235-237.
Khan et al., Journal of Allergy and Clinical Immunology, vol. 119, Issue 5, Mar. 6, 2007, pp. 1277.
Brittain, Chapter V of Polymorphism in Pharmaceutical Solids, 1999, pp. 126-127.

Affiliated with

Also associated with

Rating

Kinase inhibitors and their uses does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Kinase inhibitors and their uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Kinase inhibitors and their uses will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4283568